KD
Koluka Dileepkumar
About Koluka Dileepkumar
Koluka Dileepkumar has 13 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including G9 Investech Private Limited and Omwaltz Healthcare Private Limited. Formerly with 2 companies, such as Sri Venkata Lakshmi Narasimha Ventures Llp. Engaged in Technology, Healthcare and more. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
G9 Investech Private Limited
U72900KA2022PTC166230
|
Director | 19 Sep 2022 | 2022 | Active |
Celerity E-Services Llp
AAD-2445
|
Designated Partner | 21 Jan 2015 | 2015 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
| Designated Partner | 22 Jul 2025 | 2023 | Active | |
Omwaltz Healthcare Private Limited
U85110KA2012PTC065902
|
Director | 13 Sep 2012 | 2012 | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Koluka Dileepkumar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Koluka Dileepkumar
Koluka Dileepkumar has 13 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including G9 Investech Private Limited and Omwaltz Healthcare Private Limited. Formerly with 2 companies, such as Sri Venkata Lakshmi Narasimha Ventures Llp. Engaged in Technology, Healthcare and more. Contributes to corporate operations.
Koluka Dileepkumar is associated with 2 companies as Director and Designated Partner.
Koluka Dileepkumar has expertise in Technology, Healthcare and other sectors.
Koluka Dileepkumar has 13 years in corporate governance.